Hepatobiliary is the most common illness in China. There are 93 million Hepatitis B carriers in China. Among these carriers, there are 20~30 million patients in virus active period; however, less than 10 million patients have taken antiviral agents formally. At present, nucleoside and long acting interferon are the main strain for the antiviral agents. Especially, nucleoside takes 80% share in antiviral agents market; the main products include Entecavir, Tenofovir and Lamivudine.